Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoCHGCF +2.10%89 Equity-to-Asset is 0.83 as of Jun. 2026, which is 1% above its 10-year median of 0.82. GuruFocus rates CHGCF with a GF Score™ of 89/100 and a GF Value™ of $47.40 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 84.79% on this metric.
Chugai Pharmaceutical Co (OTCPK:CHGCF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Chugai Pharmaceutical Co Equity-to-Asset Related Terms
Chugai Pharmaceutical Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHGCF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Equity-to-Asset falls into.
Chugai Pharmaceutical Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Chugai Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (CHGCF) has a Equity-to-Asset of 0.83 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Chugai Pharmaceutical Co and its competitors. This is near median its historical median of 0.82. Over the past decade, Chugai Pharmaceutical Co's Equity-to-Asset has ranged from 0.76 to 0.89. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #153 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 15.2%.
Is Chugai Pharmaceutical Co's Equity-to-Asset too high?
Chugai Pharmaceutical Co's current Equity-to-Asset of 0.83 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 0.89. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Chugai Pharmaceutical Co's value of 0.83 is 38.3% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #153 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #153 out of 1006 companies for Equity-to-Asset. This places Chugai Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. Chugai Pharmaceutical Co's value of 0.83 is 38.3% above this benchmark. Historically, Chugai Pharmaceutical Co's own Equity-to-Asset has ranged from 0.76 to 0.89 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.60, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Equity-to-Asset of 0.83 is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Equity-to-Asset is 0.83, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Fairly Valued. The stock's GF Value™ is $47.40, compared to a current price of $43.78 — trading 7.6% below its estimated fair value. The current Equity-to-Asset is 0.83, which is near median its 10-year median of 0.82 and 38.3% above the Drug Manufacturers industry median of 0.60. Chugai Pharmaceutical Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Equity-to-Asset is 0.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $43.78 is trading 7.6% below its estimated GF Value™ of $47.40.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCF:
Equity-to-Asset: 0.83 (near median its 10-year median of 0.82)
GF Value™: $47.40 vs. price of $43.78 (7.6% below fair value)
Industry Position: 38.3% above the Drug Manufacturers median (#153 of 1006)
No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
89GF Score
Get the complete analysis for CHGCF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCF has been successfully added to your 
